// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1671 Abstracts

Simple and rapid enrichment of circulating tumor cells (CTCs) for RNAseq in metastatic castrate resistant prostate cancer (mCRPC).

Gareth Morrison - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A highly efficient, low-cost, novel multicomponent nanosystem for rapid enumeration of circulating tumor cells.

Jayant Khandare - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

glutathione

Clinical significance of circulating tumor cells identified by cell-surface vimentin in pancreatic cancer.

Tao Wei - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Can the enumeration of circulating tumor cells (CTCs) and the characterization of circulating tumor DNA (ctDNA) provide insight into organ tropism in metastatic breast cancer (MBC)?

Lorenzo Gerratana - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Imaging features of genomic instability in circulating tumor cells (CTCs) from metastatic triple-negative breast cancer (metTNBC) patients (pts) who received PIKTOR.

Priscilla Ontiveros - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Sapanisertib

Diagnostic value of cytokeratin-1, survivin and TG expression in circulating tumor cells in the differentiation of benign and malignant thyroid nodules.

Jie Liu - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma.

Carolina Reduzzi - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Pathologic complete response and serial circulating tumor cell monitoring during neoadjuvant therapy in nonmetastatic triple-negative breast cancer patients.

Carolyn S. Hall - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor cells in patients with locally advanced breast cancer in evaluation of antitumor treatment efficacy.

Aleksandr B. Sagakyants - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.

Ippokratis Messaritakis - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Etoposide

TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.

Joaquin Mateo - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Olaparib

Quantification of activated and exhausted immune cell populations and simultaneous characterization of circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy.

Gordon Vansant - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

CTC enumeration and characterization as a pharmacodynamic marker in the phase I clinical study of APX3330, an APE1/Ref-1 inhibitor, in patients with advanced solid tumors.

Lincy Chu - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

E-3330

Dynamic change of PD-L1 expression on circulating tumor cells in advanced breast cancer undergoing PD-1 blockade therapy.

Tao Wang - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating cell-free tumor DNA chromosomal instability and circulating tumor cells as tools to predict microvascular invasion of hepatocellular carcinoma.

Jin Wang - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Morphologic and genomic characterization of circulating tumor cells in patients with metastatic colorectal cancer treated with combinational treatment of andecaliximab, bevacizumab and chemotherapy.

Stephanie Shishido - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bevacizumab

Functional cell profiling (FCP) of ~100,000 CTCs from multiple cancer types identifies morphologically distinguishable CTC subtypes within and between cancer types.

Gordon Vansant - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Chronotherapeutic regimen with liposomal cisplatin for systemic treatment of primary liver cancer.

Levan Tavartkiladze - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cisplatin

Clinical observation of low-dose apatinib in the treatment of small cell lung cancer with antidiuretic hormone secretion.

Yuming Jia - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Apatinib

Role of the expression of PD-L1 and CD47 on circulating tumor cells (CTCs) in the prediction of outcome in metastatic breast cancer (mBC) patients.

Sofia Agelaki - American Society of Clinical Oncology (ASCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved